Hansa Biopharma AB (publ) (HNSBF) Discusses Top Line Results from PAES Study on Imlifidase in Highly Sensitized Kidney Transplant Patients - Slideshow
Hansa Biopharma AB has released top line results from the PAES study on Imlifidase, which is aimed at highly sensitized kidney transplant patients. The findings were shared in a recent slide deck published by the company. This study represents a significant step in addressing the challenges faced by this patient population.
- ▪Hansa Biopharma AB discussed the results from the PAES study on Imlifidase.
- ▪The study focuses on highly sensitized kidney transplant patients.
- ▪The results were published in a slide deck accompanying the event.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4909290-hansa-biopharma-ab-publ-hnsbf-discusses-top-line-results-from-paes-study-on-imlifidase-in"},"author":{"@type":"Person","name":"SA Transcripts","url":"https://seekingalpha.com/author/sa-transcripts"},"publisher":{"@context":"http://schema.org","@type":"Organization","address":{"@type":"PostalAddress","streetAddress":"244 5th Ave","addressLocality":"New York","addressRegion":"NY","postalCode":"10001","addressCountry":"US"},"alternateName":["SeekingAlpha","SA"],"brand":[{"@type":"Brand","name":"Seeking Alpha Premium","url":"https://seekingalpha.com/subscriptions/premium"},{"@type":"Brand","name":"Seeking Alpha…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
